GlaxoSmithKline in a Rare-Disease Pact with Prosensa for RNA-modulation Drugs
This article was originally published in The Pink Sheet Daily
GSK is paying £16m ($25m) upfront for rights to Prosensa's lead Duchenne's compound, and takes hallmark options to related candidates.
You may also be interested in...
The upcoming Therapeutic Area Partnership conference will showcase companies in niche areas that are prime targets for partnerships or acquisitions.
Sarepta Therapeutics’ positive data on its lead muscular dystrophy drug eteplirsen puts the company in a strong position at the partnering table and sets the stage for a neck and neck race with GSK/Prosensa to bring the first treatment for the rare disease to market.
The RNA drug-discovery company, formerly AVI BioPharma, is reinventing itself as an orphan disease drug specialist called Sarepta Therapeutics. With the release of positive Phase IIb data on its lead candidate for Duchenne muscular dystrophy, the transformation has gotten a big boost.